These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31766977)

  • 21. Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
    Khan JN; Greenwood JP; Nazir SA; Lai FY; Dalby M; Curzen N; Hetherington S; Kelly DJ; Blackman D; Peebles C; Wong J; Flather M; Swanton H; Gershlick AH; McCann GP
    J Am Heart Assoc; 2016 May; 5(6):. PubMed ID: 27247336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
    Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y
    Franchi F; James SK; Ghukasyan Lakic T; Budaj AJ; Cornel JH; Katus HA; Keltai M; Kontny F; Lewis BS; Storey RF; Himmelmann A; Wallentin L; Angiolillo DJ;
    J Am Heart Assoc; 2019 Mar; 8(6):e011139. PubMed ID: 30857464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
    Diodati JG; Saucedo JF; French JK; Fung AY; Cardillo TE; Henneges C; Effron MB; Fisher HN; Angiolillo DJ
    Circ Cardiovasc Interv; 2013 Oct; 6(5):567-74. PubMed ID: 24065443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
    Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
    Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy with ticagrelor for ST-elevated acute coronary syndrome accompanied by diabetes mellitus.
    Liu Y; Ding LY; Li XZ
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):312-318. PubMed ID: 31389599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study.
    Schnorbus B; Daiber A; Jurk K; Warnke S; König J; Krahn U; Lackner K; Munzel T; Gori T
    BMJ Open; 2014 May; 4(5):e005268. PubMed ID: 24801283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
    Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
    Pourdjabbar A; Hibbert B; Chong AY; Le May MR; Labinaz M; Simard T; Ramirez FD; Lugomirski P; Maze R; Froeschl M; Glover C; Dick A; Marquis JF; Bernick J; Wells G; So DY;
    Thromb Haemost; 2017 Jan; 117(2):303-310. PubMed ID: 27761582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Society Guidelines on Trends in Use of Newer P2Y
    Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA
    J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices.
    Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD
    Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
    Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
    JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Cangrelor on Infarct Size in ST-Segment-Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial).
    Bulluck H; Chong JH; Bryant J; Annathurai A; Chai P; Chan M; Chawla A; Chin CY; Chung YC; Gao F; Ho HH; Ho AFW; Hoe J; Imran SS; Lee CH; Lim B; Lim ST; Lim SH; Liew BW; Zhan Yun PL; Ong MEH; Paradies V; Pung XM; Tay JCK; Teo L; Ting BP; Wong A; Wong E; Watson T; Chan MY; Keong YK; Tan JWC; Hausenloy DJ;
    Circulation; 2024 Jul; 150(2):91-101. PubMed ID: 38742915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.